JP2002524421A5 - - Google Patents

Download PDF

Info

Publication number
JP2002524421A5
JP2002524421A5 JP2000568510A JP2000568510A JP2002524421A5 JP 2002524421 A5 JP2002524421 A5 JP 2002524421A5 JP 2000568510 A JP2000568510 A JP 2000568510A JP 2000568510 A JP2000568510 A JP 2000568510A JP 2002524421 A5 JP2002524421 A5 JP 2002524421A5
Authority
JP
Japan
Prior art keywords
composition
vegf
hus
factor
organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000568510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002524421A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/020480 external-priority patent/WO2000013702A2/en
Publication of JP2002524421A publication Critical patent/JP2002524421A/ja
Publication of JP2002524421A5 publication Critical patent/JP2002524421A5/ja
Pending legal-status Critical Current

Links

JP2000568510A 1998-09-09 1999-09-09 微小血管障害の処置 Pending JP2002524421A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US12640699P 1999-03-26 1999-03-26
US12661599P 1999-03-27 1999-03-27
US60/099,694 1999-03-27
US60/126,406 1999-03-27
US60/126,615 1999-03-27
PCT/US1999/020480 WO2000013702A2 (en) 1998-09-09 1999-09-09 Use of an angiogenic factor for the treatment of microvascular angiopathies

Publications (2)

Publication Number Publication Date
JP2002524421A JP2002524421A (ja) 2002-08-06
JP2002524421A5 true JP2002524421A5 (cg-RX-API-DMAC7.html) 2006-10-26

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000568511A Pending JP2002532382A (ja) 1998-09-09 1999-09-09 高血圧を処置する方法およびそこでの使用のための組成物
JP2000568510A Pending JP2002524421A (ja) 1998-09-09 1999-09-09 微小血管障害の処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000568511A Pending JP2002532382A (ja) 1998-09-09 1999-09-09 高血圧を処置する方法およびそこでの使用のための組成物

Country Status (13)

Country Link
US (3) US6352975B1 (cg-RX-API-DMAC7.html)
EP (2) EP1112083B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002532382A (cg-RX-API-DMAC7.html)
AT (2) ATE253934T1 (cg-RX-API-DMAC7.html)
AU (2) AU5910599A (cg-RX-API-DMAC7.html)
BR (2) BR9913533A (cg-RX-API-DMAC7.html)
CA (2) CA2340728C (cg-RX-API-DMAC7.html)
DE (2) DE69912815T2 (cg-RX-API-DMAC7.html)
DK (2) DK1112083T3 (cg-RX-API-DMAC7.html)
ES (2) ES2211165T3 (cg-RX-API-DMAC7.html)
IL (2) IL141686A0 (cg-RX-API-DMAC7.html)
PT (2) PT1109571E (cg-RX-API-DMAC7.html)
WO (2) WO2000013702A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253934T1 (de) * 1998-09-09 2003-11-15 Scios Inc Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
JP2003513105A (ja) * 1999-11-02 2003-04-08 ジェネンテック・インコーポレーテッド eNOS活性の調節とその治療的使用
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU2002317333C1 (en) 2001-08-01 2009-06-25 University Of Bristol VEGF isoform
US7432301B2 (en) * 2001-08-20 2008-10-07 University Of Virginia Patent Foundation Use of S-nitrosothiol signaling to treat disordered control of breathing
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのRNAi治療用の組成物および方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
EP1964568B1 (en) * 2005-08-31 2014-03-26 National University Corporation Kagawa University Utilization of hypertension/hypercardia-preventing effect of d-allose
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
GB0921525D0 (en) 2009-12-08 2010-01-27 Isis Innovation Product and method
WO2018183625A1 (en) 2017-03-30 2018-10-04 Wake Forest University Health Sciences Methods of treatment for kidney disease
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
ES2103740T3 (es) 1989-03-24 1997-10-01 Univ California Factor de crecimiento celular endotelialico, su aislamiento y su expresion.
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
AU729420B2 (en) * 1996-11-01 2001-02-01 Eurogene Limited Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
ATE253934T1 (de) * 1998-09-09 2003-11-15 Scios Inc Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien

Similar Documents

Publication Publication Date Title
Shah et al. Comparative evaluation of platelet-rich fibrin with demineralized freeze-dried bone allograft in periodontal infrabony defects: A randomized controlled clinical study
US10314861B2 (en) Flowable tissue matrices
Ruszczak Effect of collagen matrices on dermal wound healing
US9004918B2 (en) Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chitosan
US20200022798A1 (en) Method for elimination of space through tissue approximation
Omata et al. Enhanced bone regeneration by gelatin–β‐tricalcium phosphate composites enabling controlled release of bFGF
JP2002531193A (ja) 生きた組織を再生するための方法および物品
JP2015534945A (ja) 幹細胞を動員および局在化するための組成物および方法
JP2002506831A5 (cg-RX-API-DMAC7.html)
CN106668840B (zh) 一种胰岛素控释药物及其制备方法与应用
US20070098759A1 (en) Method for regenerating cartilage
CA2263557C (en) Implant consisting of a carrier material containing medical substances and method to produce such an implant
JP2010518946A5 (cg-RX-API-DMAC7.html)
EP3302523B1 (fr) Composition pour le traitement des lesions tissulaires
US20170368231A1 (en) Bioengineered Regenerative Graft Matrix, and Methods for Making Thereof
JP2022514152A5 (cg-RX-API-DMAC7.html)
Nie et al. Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model
DE3240909A1 (de) Zubereitung zur wundheilung und verfahren zu ihrer herstellung
KR102189850B1 (ko) 생리활성인자가 탑재된 고분자-세포 혼합 스페로이드 및 이의 제조방법
Yukna et al. Evaluation of resultant tissue type following the intraoral transplantatin of various lyophilized soft tissues
JP2008536930A5 (cg-RX-API-DMAC7.html)
JP2002534393A5 (cg-RX-API-DMAC7.html)
US20070020245A1 (en) Composition for the treatment of arthrosis/arthritis, especially for treating joints
JP2006176408A (ja) 水蛭粉末の製造方法及び該製造方法によって得られた水蛭粉末、該水蛭粉末を含有する血栓溶解促進組成物
CN100479868C (zh) 激光微孔猪去细胞真皮基质及其制备方法和应用